Understanding Immunotherapy Trials in Type 1 Diabetes

For decades, insulin and insulin delivery systems were the main tools for managing Type 1 diabetes. That changed when teplizumab, an immunotherapy medication, became the first drug approved to delay Type 1 diabetes onset.

In clinical trials, teplizumab delayed the development of symptoms in people at high risk. This approval opens new possibilities for people who have early warning signs but have not yet developed Type 1 diabetes.

Researchers are now testing immunotherapies at different stages. Prevention trials enroll people at high risk before symptoms appear. Recent-onset trials enroll people recently diagnosed with Type 1 diabetes. Organizations like TrialNet and the Immune Tolerance Network (ITN) are leading these efforts.

Trials typically begin in adults to establish safety before expanding to children. Several trials are currently enrolling or planning to launch soon.

Type 1 diabetes researchers are adapting approaches that have shown promise in other autoimmune diseases and conditions like cancer. These methods are being tested to see if they work for Type 1 diabetes.

Scientists are also exploring combination strategies. These pair immunotherapies with treatments meant to protect and preserve beta cells—the insulin-producing cells in the pancreas. The idea is that combining different approaches may work better than any single therapy alone.

The approval of teplizumab and new clinical trials represent a shift from managing symptoms to potentially slowing or changing how Type 1 diabetes develops. These treatments do not cure Type 1 diabetes, but delaying onset can meaningfully affect daily life, especially for children.

As trials progress and researchers test new combinations, Type 1 diabetes treatment is expected to continue evolving. This reflects a fundamental change in how the medical community approaches the condition.

Source: YouTube community video. Evidence type: Community video — lay discussion, not peer-reviewed research. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.